Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2014

View Archived Issues

Whole-exome sequencing links motor neuron disease and neurodegenerative disorders

Zenith Epigenetics identifies new compounds for epigenetics drug discovery

Catalyst Biosciences presents new polypeptides for coagulation disorders

FDA grants orphan drug status to "lost" drug for AML

Prana Biotechnology reports phase II results in Huntington's disease trial

Researchers at Biogen Idec prepare novel autotaxin inhibitors

Elite Pharmaceuticals reports data from pilot bioequivalence study of ELI-201

Supplemental NDA for Lymphoseek granted priority review by FDA

New seriniquinone derivatives with utility for cancer

Servier Canada invests in two research projects supported by Quebec government

French group discloses novel CYP26A1 inhibitors for dermatological disorders

RaQualia Pharma collaborates with Nagoya University

Millennium Pharmaceuticals synthesizes new UBA6 inhibitors for cancer

CNB-001 demonstrates promising neuroprotective activity in vivo

Genfit's GFT-505 granted FDA fast track designation

Boehringer Ingelheim divulges novel PDE2A inhibitors

Dynavax withdraws European marketing application for Heplisav

Japanese researchers design new delta opioid receptor agonists

Vital Therapies enrolls first subject in Europe in VTI-208 study

DNA hypermethylation associated with shortened PFS in patients with RCC

Second phase Ib trial of OMP-54F28 with Nexavar in HCC begins

International Stem Cell Corp. and FDA hold pre-IND meeting for Parkinson's disease cell therapy

FDA grants accelerated approval to Northera in symptomatic NOH

Eleven Biotherapeutics begins pivotal phase III study of EBI-005

FDA approves California Stem Cell's phase II stem trial for ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...